Solid Biosciences Statistics
Share Statistics
Solid Biosciences has 39.95M shares outstanding. The number of shares has increased by 91.28% in one year.
| Shares Outstanding | 39.95M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.56% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 32.78M |
| Failed to Deliver (FTD) Shares | 4.73K |
| FTD / Avg. Volume | 1.6% |
Short Selling Information
The latest short interest is 1.48M, so 3.71% of the outstanding shares have been sold short.
| Short Interest | 1.48M |
| Short % of Shares Out | 3.71% |
| Short % of Float | 4.55% |
| Short Ratio (days to cover) | 4.44 |
Valuation Ratios
The PE ratio is -1.27 and the forward PE ratio is -1.97.
| PE Ratio | -1.27 |
| Forward PE | -1.97 |
| PS Ratio | 0 |
| Forward PS | 132.4 |
| PB Ratio | 0.97 |
| P/FCF Ratio | -1.28 |
| PEG Ratio | n/a |
Enterprise Valuation
Solid Biosciences Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 8.94, with a Debt / Equity ratio of 0.21.
| Current Ratio | 8.94 |
| Quick Ratio | 8.94 |
| Debt / Equity | 0.21 |
| Total Debt / Capitalization | 17.2 |
| Cash Flow / Debt | -3.59 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.76% and return on capital (ROIC) is -68.29%.
| Return on Equity (ROE) | -0.76% |
| Return on Assets (ROA) | -0.58% |
| Return on Capital (ROIC) | -68.29% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.09M |
| Employee Count | 88 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -5.01% in the last 52 weeks. The beta is 1.93, so Solid Biosciences 's price volatility has been higher than the market average.
| Beta | 1.93 |
| 52-Week Price Change | -5.01% |
| 50-Day Moving Average | 5.7 |
| 200-Day Moving Average | 8.16 |
| Relative Strength Index (RSI) | 40.55 |
| Average Volume (20 Days) | 295.23K |
Income Statement
In the last 12 months, Solid Biosciences had revenue of $0 and earned -$96.02M in profits. Earnings per share was $-4.83.
| Revenue | 0 |
| Gross Profit | -76.56M |
| Operating Income | -104.31M |
| Net Income | -96.02M |
| EBITDA | -93.43M |
| EBIT | - |
| Earnings Per Share (EPS) | -4.83 |
Balance Sheet
The company has $74.02M in cash and $26.27M in debt, giving a net cash position of $47.75M.
| Cash & Cash Equivalents | 74.02M |
| Total Debt | 26.27M |
| Net Cash | 47.75M |
| Retained Earnings | -658.75M |
| Total Assets | 211.83M |
| Working Capital | 156.64M |
Cash Flow
In the last 12 months, operating cash flow was -$94.18M and capital expenditures -$1.51M, giving a free cash flow of -$95.69M.
| Operating Cash Flow | -94.18M |
| Capital Expenditures | -1.51M |
| Free Cash Flow | -95.69M |
| FCF Per Share | -4.81 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
SLDB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -97.97% |
| FCF Yield | -48.58% |
Analyst Forecast
The average price target for SLDB is $15.5, which is 214.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.5 |
| Price Target Difference | 214.4% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Stock Splits
The last stock split was on Oct 28, 2022. It was a backward split with a ratio of 1:15.
| Last Split Date | Oct 28, 2022 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -3.15 |
| Piotroski F-Score | 2 |